Shares of Aclarion, Inc. (NASDAQ: ACON) are seeing a recovery today, partially recovering a previous-session drop. As of the last premarket check, ACON stock was trading 8.36% up at $3.50. Even if there was no immediate news that caused the price to change, recent developments could have contributed to the resurgence of investor interest.
Cutting Edge Technology on Display at the 2025 Spine Summit
Distinguished orthopedic surgeon Dr. Nicholas Theodore highlighted the revolutionary potential of Aclarion’s in-house technology, NOCISCAN, at the company’s recent participation in the 2025 Spine Summit last week. By combining augmented intelligence with magnetic resonance (MR) spectroscopy, this cutting-edge tool seeks to transform spine surgery by offering noninvasive, objective diagnostic insights.
Dr. Theodore emphasized how NOCISCAN improves the accuracy of chronic low back pain (cLBP) diagnosis. With approximately 266 million people worldwide suffering from degenerative spine disease and low back pain, Aclarion’s technology offers a critical tool for identifying pain sources that are undetectable through traditional imaging.
ACON’s Industry Standing and Peer Comparisons
ACON currently holds a score of 34 on our screener and is categorized within the Medical Healthcare Information Services industry. To provide a broader market perspective, we have compiled a list of peer stocks that have achieved higher scores and received “Buy” analyst recommendations. This exclusive compilation can be accessed through our ST screener link, offering investors valuable insights into potentially stronger investment opportunities.
Aclarion Strengthening its Portfolio
Along with its technological innovations, Aclarion recently received a Notice of Allowance for its 24th granted U.S. patent from the United States Patent and Trademark Office (USPTO). This new invention expands the application to detect propionic acid (PA) throughout the body, whereas earlier patents concentrated on employing MR spectroscopy to detect PA in spinal discs.
This development strengthens Aclarion’s position as a pioneer in cutting-edge medical diagnostics by improving its capacity to pinpoint possible infection and pain origins. Aclarion continues to lead the way in spine diagnostics, opening the door for better patient outcomes and wider clinical use with its innovative technology, ongoing patent acquisitions, and increasing industry recognition.